Novartis’ Femara Improves Disease-Free Survival In Breast Cancer Patients Post Tamoxifen – JCO Article
This article was originally published in The Pink Sheet Daily
Executive Summary
Cohort analysis demonstrates treatment with letrozole one to seven years after tamoxifen therapy led to 63 percent reduction in disease recurrence.
You may also be interested in...
Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Novartis’ oncology chief discusses in-licensing candidates, as well as how biologics fit into the firm’s oncology pipeline.
Femara Gets Indication for Early-Stage Breast Cancer
Novartis touts a New England Journal of Medicine article stating that letrozole is superior to tamoxifen.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.